A new drug against breast cancer that has been approved by the Ministry of Health will considerably reduce the time of a treatment.
Phesgo, a combination of Perjeta and Herceptin, is the drug in question. A fixed dose with hyaluronidase that is delivered by subcutaneous injection.
This treatment against early HER2-positive and metastatic breast cancer will allow much faster administration than the intravenous one that has been used with pertuzumab and trastuzumab.
Regarding this new drug, Dr. Beatriz Pérez has pointed out that “it is an important step forward in the treatment of this type of breast cancer, since it makes it possible to significantly reduce the time that people spend receiving standard therapy.”
In this way, the impact that the treatment has on the patient’s day-to-day will be minimized.
#drug #breast #cancer #reduces #treatment #minutes